atai beckley nv - ATAI
ATAI
Close Chg Chg %
3.67 0.05 1.36%
Pre-Market
3.72
+0.05 (1.36%)
Volume: 4.24M
Last Updated:
Jan 14, 2026, 4:00 PM EDT
Company Overview: atai beckley nv - ATAI
ATAI Key Data
| Open $3.67 | Day Range 3.65 - 3.85 |
| 52 Week Range 1.15 - 6.73 | Market Cap $1.37B |
| Shares Outstanding 363.22M | Public Float 290.35M |
| Beta 1.62 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.74 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.78M |
ATAI Performance
| 1 Week | -0.80% | ||
| 1 Month | -13.29% | ||
| 3 Months | -42.33% | ||
| 1 Year | 154.79% | ||
| 5 Years | N/A |
ATAI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
12
Full Ratings ➔
About atai beckley nv - ATAI
Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.
ATAI At a Glance
Atai Beckley, Inc.
250 West 34th Street
New York, New York 10119
| Phone | 1-929-207-2670 | Revenue | 308.00K | |
| Industry | Medical/Nursing Services | Net Income | -149,269,000.00 | |
| Sector | Health Services | Employees | 54 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ATAI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 691.60 |
| Price to Book Ratio | 1.921 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.621 |
| Enterprise Value to Sales | 537.811 |
| Total Debt to Enterprise Value | 0.149 |
ATAI Efficiency
| Revenue/Employee | 5,703.704 |
| Income Per Employee | -2,764,240.741 |
| Receivables Turnover | 0.228 |
| Total Asset Turnover | 0.001 |
ATAI Liquidity
| Current Ratio | 3.211 |
| Quick Ratio | 3.211 |
| Cash Ratio | 2.899 |
ATAI Profitability
| Gross Margin | -53.571 |
| Operating Margin | -33,341.234 |
| Pretax Margin | -48,353.896 |
| Net Margin | -48,463.961 |
| Return on Assets | -65.922 |
| Return on Equity | -83.098 |
| Return on Total Capital | -105.862 |
| Return on Invested Capital | -76.484 |
ATAI Capital Structure
| Total Debt to Total Equity | 21.244 |
| Total Debt to Total Capital | 17.522 |
| Total Debt to Total Assets | 15.501 |
| Long-Term Debt to Equity | 12.782 |
| Long-Term Debt to Total Capital | 10.542 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Atai Beckley Nv - ATAI
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 20.38M | 233.00K | 314.00K | 308.00K | |
Sales Growth
| - | -98.86% | +34.76% | -1.91% | |
Cost of Goods Sold (COGS) incl D&A
| 47.00K | 168.00K | 319.00K | 473.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 47.00K | 168.00K | 319.00K | 473.00K | |
Depreciation
| 47.00K | 168.00K | 319.00K | 273.00K | |
Amortization of Intangibles
| - | - | - | 200.00K | - |
COGS Growth
| +95.83% | +257.45% | +89.88% | +48.28% | |
Gross Income
| 20.33M | 65.00K | (5.00K) | (165.00K) | |
Gross Income Growth
| +84,804.17% | -99.68% | -107.69% | -3,200.00% | |
Gross Profit Margin
| +99.77% | +27.90% | -1.59% | -53.57% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 140.65M | 144.50M | 125.47M | 102.53M | |
Research & Development
| 47.91M | 74.15M | 61.88M | 54.98M | |
Other SG&A
| 92.75M | 70.35M | 63.58M | 47.54M | |
SGA Growth
| +35.07% | +2.73% | -13.17% | -18.28% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 24.67M | (2.36M) | (85.63M) | 42.15M | |
EBIT after Unusual Expense
| (144.99M) | (142.07M) | (39.84M) | (144.84M) | |
Non Operating Income/Expense
| 8.39M | 6.89M | 3.21M | (969.00K) | |
Non-Operating Interest Income
| 205.00K | 548.00K | 1.85M | 778.00K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 2.66M | 3.12M | - |
Interest Expense Growth
| - | - | - | +17.62% | - |
Gross Interest Expense
| - | - | 2.66M | 3.12M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (136.60M) | (135.18M) | (39.29M) | (148.93M) | |
Pretax Income Growth
| -34.17% | +1.04% | +70.94% | -279.09% | |
Pretax Margin
| -670.40% | -58,018.03% | -12,511.46% | -48,353.90% | |
Income Tax
| (3.99M) | 6.23M | 1.02M | (881.00K) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| 1.12M | 1.16M | 1.02M | (356.00K) | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | (5.11M) | 5.07M | - |
Income Tax Credits
| - | - | - | 525.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (174.24M) | (157.42M) | (43.90M) | (150.05M) | |
Minority Interest Expense
| (6.44M) | (5.03M) | (3.67M) | (780.00K) | |
Net Income
| (167.81M) | (152.39M) | (40.22M) | (149.27M) | |
Net Income Growth
| +1.20% | +9.19% | +73.60% | -271.09% | |
Net Margin Growth
| -823.56% | -65,401.29% | -12,810.19% | -48,463.96% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (167.81M) | (152.39M) | (40.22M) | (149.27M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (167.81M) | (152.39M) | (40.22M) | (149.27M) | |
EPS (Basic)
| -1.0444 | -0.9786 | -0.2532 | -0.932 | |
EPS (Basic) Growth
| +96.43% | +6.30% | +74.13% | -268.09% | |
Basic Shares Outstanding
| 160.68M | 155.72M | 158.83M | 160.16M | |
EPS (Diluted)
| -1.0444 | -0.9786 | -0.2532 | -0.932 | |
EPS (Diluted) Growth
| +96.43% | +6.30% | +74.13% | -268.09% | |
Diluted Shares Outstanding
| 160.68M | 155.72M | 158.83M | 160.16M | |
EBITDA
| (120.28M) | (144.26M) | (125.15M) | (102.22M) | |
EBITDA Growth
| -15.50% | -19.94% | +13.25% | +18.32% | |
EBITDA Margin
| -590.29% | -61,915.02% | -39,857.32% | -33,187.66% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 12.40 | |
| Number of Ratings | 12 | Current Quarters Estimate | -0.102 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.456 | |
| Last Quarter’s Earnings | -0.11 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.64 | Next Fiscal Year Estimate | -0.469 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 12 | 9 |
| Mean Estimate | -0.10 | -0.12 | -0.46 | -0.47 |
| High Estimates | -0.07 | -0.08 | -0.30 | -0.34 |
| Low Estimate | -0.17 | -0.28 | -0.99 | -0.86 |
| Coefficient of Variance | -30.85 | -52.94 | -43.68 | -34.90 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 12 | 12 | 11 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Atai Beckley Nv - ATAI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Atai Beckley Nv - ATAI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 25, 2025 | Robert M. Hershberg Director | 456,011 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 25, 2025 | Robert M. Hershberg Director | 97,716 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 25, 2025 | Robert M. Hershberg Director | 62,394 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 25, 2025 | Robert M. Hershberg Director | 103,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 25, 2025 | Srinivas G. Rao See Remarks | 212,942 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 287,471.70 |
| Mar 25, 2025 | Glenn Short Chief Scientific Officer | 42,333 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 57,149.55 |
| Mar 25, 2025 | Apeiron Partners | 42,369,415 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.4 per share | 59,317,181.00 |
| Mar 25, 2025 | Kevin Craig Chief Medical Officer | 8,437 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 11,389.95 |
| Mar 25, 2025 | Anne Johnson Chief Financial Officer | 140,045 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 189,060.75 |
| Mar 25, 2025 | Sahil Kirpekar Chief Business Officer | 115,636 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 156,108.60 |
| Mar 21, 2025 | Srinivas G. Rao See Remarks | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Glenn Short Chief Scientific Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Kevin Craig Chief Medical Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Anne Johnson Chief Financial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Sahil Kirpekar Chief Business Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |